Vanguard Group
ATRA icon

Vanguard Group’s Atara Biotherapeutics ATRA Stock Holding History

Vanguard Group’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$4.09M Buy
225,940
+22,502
+11% +$336K ﹤0.01% 3330
2025
Q3 		$2.92M Buy
203,438
+12,677
+7% +$146K ﹤0.01% 3454
2025
Q2 		$1.47M Hold
190,761
– – ﹤0.01% 3636
2025
Q1 		$1.13M Buy
190,761
+11,979
+7% +$105K ﹤0.01% 3673
2024
Q4 		$2.38M Sell
178,782
-1,933
-1% -$20.4K ﹤0.01% 3510
2024
Q3 		$1.47M Buy
180,715
+11,379
+7% +$97.5K ﹤0.01% 3655
2024
Q2 		$1.44M Sell
169,336
-31,182
-16% -$469K ﹤0.01% 3671
2024
Q1 		$3.48M Sell
200,518
-66,924
-25% -$1.19M ﹤0.01% 3425
2023
Q4 		$3.43M Buy
267,442
+3,205
+1% +$74.7K ﹤0.01% 3422
2023
Q3 		$9.78M Sell
264,237
-13,616
-5% -$606K ﹤0.01% 2897
2023
Q2 		$11.2M Buy
277,853
+3,646
+1% +$206K ﹤0.01% 2876
2023
Q1 		$19.9M Sell
274,207
-14,235
-5% -$1.38M ﹤0.01% 2584
2022
Q4 		$23.7M Buy
288,442
+24,182
+9% +$2.52M ﹤0.01% 2543
2022
Q3 		$25M Sell
264,260
-27,663
-9% -$3.11M ﹤0.01% 2538
2022
Q2 		$56.9M Buy
291,923
+15,420
+6% +$2.52M ﹤0.01% 2139
2022
Q1 		$64.2M Sell
276,503
-6,518
-2% -$2.08M ﹤0.01% 2180
2021
Q4 		$112M Buy
283,021
+10,998
+4% +$4.63M ﹤0.01% 1928
2021
Q3 		$122M Buy
272,023
+3,857
+1% +$1.38M ﹤0.01% 1877
2021
Q2 		$104M Buy
268,166
+14,054
+6% +$5.01M ﹤0.01% 1981
2021
Q1 		$91.2M Buy
254,112
+28,581
+13% +$12.6M ﹤0.01% 1998
2020
Q4 		$111M Buy
225,531
+33,561
+17% +$15.5M ﹤0.01% 1780
2020
Q3 		$62.2M Buy
191,970
+6,265
+3% +$2.13M ﹤0.01% 1903
2020
Q2 		$67.6M Buy
185,705
+32,812
+21% +$8.29M ﹤0.01% 1849
2020
Q1 		$32.5M Buy
152,893
+5,625
+4% +$1.79M ﹤0.01% 2058
2019
Q4 		$60.6M Buy
147,268
+4,010
+3% +$1.38M ﹤0.01% 2012
2019
Q3 		$50.6M Buy
143,258
+22,794
+19% +$8.5M ﹤0.01% 2057
2019
Q2 		$60.6M Buy
120,464
+5,291
+5% +$3.73M ﹤0.01% 2000
2019
Q1 		$114M Buy
115,173
+2,515
+2% +$2.34M ﹤0.01% 1681
2018
Q4 		$97.8M Buy
112,658
+13,155
+13% +$12.2M ﹤0.01% 1694
2018
Q3 		$103M Buy
99,503
+4,249
+4% +$4.15M ﹤0.01% 1788
2018
Q2 		$87.5M Buy
95,254
+31,980
+51% +$34.4M ﹤0.01% 1850
2018
Q1 		$61.7M Buy
63,274
+25,774
+69% +$23.5M ﹤0.01% 1964
2017
Q4 		$17M Buy
37,500
+774
+2% +$286K ﹤0.01% 2558
2017
Q3 		$15.2M Buy
36,726
+2,891
+9% +$1.09M ﹤0.01% 2607
2017
Q2 		$11.8M Buy
33,835
+558
+2% +$215K ﹤0.01% 2695
2017
Q1 		$17.1M Buy
33,277
+3,265
+11% +$1.35M ﹤0.01% 2502
2016
Q4 		$10.7M Buy
30,012
+1,970
+7% +$834K ﹤0.01% 2717
2016
Q3 		$15M Buy
28,042
+854
+3% +$464K ﹤0.01% 2499
2016
Q2 		$15.3M Buy
27,188
+4,590
+20% +$2.2M ﹤0.01% 2447
2016
Q1 		$10.8M Sell
22,598
-727
-3% -$327K ﹤0.01% 2579
2015
Q4 		$15.4M Buy
23,325
+563
+2% +$426K ﹤0.01% 2416
2015
Q3 		$17.9M Buy
22,762
+8,654
+61% +$10.6M ﹤0.01% 2335
2015
Q2 		$18.6M Buy
14,108
+5,448
+63% +$6.25M ﹤0.01% 2391
2015
Q1 		$9M Buy
8,660
+3,494
+68% +$2.31M ﹤0.01% 2693
2014
Q4 		$3.45M Buy
+5,166
New +$3.15M ﹤0.01% 3073

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Vanguard Group's ATRA Position: Q4 2025 in Review

Vanguard Group increased its Atara Biotherapeutics (ATRA) stake by 11% in Q4 2025, buying an estimated $336K and bringing the position to 225,940 shares worth $4.09M. The position accounts for ﹤0.01% of the portfolio, ranked #3330.

Vanguard Group first reported a position in ATRA in Q4 2014 and has held it in 45 quarters since. The position peaked at $122M in Q3 2021. 41 funds tracked by Wall St. Rank hold ATRA as of Q4 2025.

  • Vanguard Group held 225,940 shares of Atara Biotherapeutics worth $4.09M as of Q4 2025.
  • Vanguard Group bought 22,502 Atara Biotherapeutics shares in Q4 2025, an estimated $336K.
  • Atara Biotherapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3330 holding.
  • Vanguard Group first reported a position in Atara Biotherapeutics in Q4 2014 and has held it in 45 quarters since.
  • Vanguard Group's Atara Biotherapeutics position peaked at $122M in Q3 2021.
  • 41 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.